Calcium is a universal intracellular signaling molecule. Through variations in both the amplitude and frequency of intracellular calcium increases, the same calcium ion can elicit different responses. In this report, we investigated the effect of a calcium transient, lasting 2-5 min, on alterations in the phosphorylation state of the cytoskeletal protein, tau. Transient increases in calcium result in a prolonged (1-4 h) ϳ60% increase in tau phosphorylation at the Tau-1 epitope. These increases in tau phosphorylation appear to be more dependent upon the duration of the increase in intracellular calcium and less on the amplitude. The calcium-induced increases in tau phosphorylation are not dependent upon protein synthesis,norareproteinkinaseCorcalcium/calmodulindependent protein kinase II involved in the response. However, the calcium-induced increase in tau phosphorylation was inhibited by lithium, a noncompetitive inhibitor of glycogen synthase kinase-3␤ (GSK-3␤), and by the tyrosine kinase inhibitor, genistein. Furthermore, transient increases in calcium resulted in a prolonged increase in GSK-3␤ tyrosine phosphorylation concomitant with the increase in tau phosphorylation. Therefore, this study is the first to indicate that transient increases in intracellular calcium result in increased tyrosine phosphorylation and activation of GSK-3␤ which subsequently results in a sustained increase in the phosphorylation state of tau.
Calcium is an important intracellular messenger for neuronal signaling pathways. Cytoplasmic calcium concentrations fluctuate when extracellular calcium enters the cell and/or when calcium is released from intracellular stores, and both temporal and spatial aspects of the calcium signal are important in regulating cellular responses (1, 2) . The regulation of specific protein kinases and phosphatases by different calcium signals is likely to play a role in numerous physiological and pathological processes. For example, recent studies have demonstrated that increases in intracellular calcium differentially altered phosphorylation of the microtubule-associated protein, MAP-2, in neonatal and adult rat hippocampal slices (3) . These findings suggest that mature and immature neurons respond differently to calcium signals and this in turn results in specific phospho-dependent changes in the cytoskeleton. Considering these previous findings, it is likely that the phosphorylation and function of other cytoskeletal proteins are modulated by specific calcium signals.
Tau, a family of microtubule-associated proteins produced by alternative splicing of a single gene, is a prominent phosphoprotein of the neuronal cytoskeleton. The classical function of tau is to promote microtubule nucleation and assembly, as well as to stabilize microtubules (for review, see Ref. 4) . However, tau also appears to be involved in other cellular functions, including signal transduction (5-7) and organelle transport (8, 9) . It has been well documented that increasing the phosphorylation state of tau greatly reduces its ability to bind to and stabilize microtubules (10 -13) , and it is likely that the phosphorylation state of tau will modulate tau's ability to perform its more novel roles as well. Furthermore, it is the phosphorylation of specific sites, rather than overall extent of phosphorylation, that is apparently most important in regulating the microtubule binding and stabilizing functions of tau. For example, phosphorylation of tau at just one or two sites within the microtubule-binding region significantly inhibits microtubule binding (14, 15) . Numerous protein kinases have been shown to phosphorylate tau in vitro (for reviews, see Refs. 4 and 16), however, only a few of these kinases have been shown to phosphorylate tau in situ, and little is known about the signaling processes that activate these protein kinases and subsequently the phosphorylation of tau. Since changes in the phosphorylation state of tau directly affect the function of the protein, it is important to understand the regulation of tau phosphorylation by calcium-dependent processes.
Alterations in intracellular calcium concentrations are clearly involved in modulating the phosphorylation state of tau in situ. However, results have been decidedly mixed, and there is little consensus as to the specific effects of elevating intracellular calcium levels on tau phosphorylation. For example, acute treatment of primary neuronal cultures with calcium ionophores has been reported to both increase (17, 18) and decrease (19) tau phosphorylation. The same mixed results have been found using human neuroblastoma cell lines, as ionophore treatment resulted in both increases (20) and decreases (21) in tau phosphorylation. Increasing intracellular calcium by activation of N-methyl-D-aspartate receptors has been shown to result in the dephosphorylation of tau in rat brain slices (22) and cortical neuronal cultures (19) . Therefore, it is clear that further studies are required to elucidate the role of calcium in modulating tau phosphorylation, as well as the specific protein kinases and phosphatases involved in this process.
The goal of this study was to examine the relationship between specific temporal changes in intracellular calcium concentrations and alterations in the phosphorylation state of tau.
In this study we demonstrate for the first time that transient increases in intracellular calcium concentrations ranging in duration from 2 to 5 min result in prolonged increases in tau phosphorylation (2-4 h), which are not dependent on protein synthesis. Additionally, inhibition of glycogen synthase kinase 3␤ (GSK-3␤) 1 or tyrosine kinases blocks the calcium-induced increase in tau phosphorylation. Finally, our data indicates that in response to transient increases in intracellular calcium, the tyrosine phosphorylation state of GSK-3␤ is increased, which has been shown to result in increased activity (23) . This finding is especially interesting as GSK-3␤ has not been previously reported to be activated in response to elevations in intracellular calcium levels. This study clearly demonstrates that a brief, modest increase in intracellular calcium levels results in a prolonged increase in the phosphorylation of a prominent neuronal cytoskeletal protein and hence is likely to have long term effects on cellular structure and function.
EXPERIMENTAL PROCEDURES
Materials-Several phosphorylation-dependent and phosphorylation-independent tau antibodies were used to probe tau and examine its phosphorylation state. Tau-5 (from Dr. L. Binder) recognizes tau epitopes independent of their phosphorylation state (24) . Tau-1 (from Dr. L. Binder) recognizes tau dephosphorylated at residues 189 -207 (25, 26) . 12E8 (from Dr. P. Seubert) recognizes Ser 262/356 -phosphorylated tau (27) . PHF-1 (from Dr. P. Davies) recognizes tau phosphorylated at Ser 396/404 (28, 29) (amino acid numbering is based on the longest isoform of human brain tau (30) (16, 31) were purchased from Polymedco. The monoclonal GSK-3␤ antibody, and the horseradish peroxidase-conjugated anti-phosphotyrosine antibody RC20H were purchased from Transduction Labs. The polyclonal tau antibody was from DAKO. Horseradish peroxidase-conjugated secondary antibodies were from Bio-Rad. Protein A-and protein G-Sepharose beads, phorbol 12-myristate 13-acetate, A23187, and cycloheximide were purchased from Sigma. 4-Bromo-A23187, KN-62, and KN-93 were purchased from BioMol. Cell culture media and other reagents were obtained either from Life Technologies, Inc. or Sigma, unless otherwise indicated. Drugs were dissolved in dimethyl sulfoxide (Me 2 SO)(Sigma), and the final concentration of Me 2 SO during drug treatments was maintained at 0.2% or less.
Cell Culture-Human neuroblastoma SH-SY5Y cells were maintained on Corning dishes in RPMI 1640 media supplemented with 10% horse serum, 5% fetal clone II (HyClone), 1% penicillin G, 1% streptomycin, and 20 mM L-glutamine. Cells were used in an experiment when 70 -80% confluent.
Treatments-Prior to treatment, cells were transferred to serum-free media supplemented with antibiotics and 20 mM L-glutamine. Cells were then treated with A23187, a selective calcium ionophore, or other drugs as indicated, and returned to the incubator at 5% CO 2 and 37°C for the indicated amount of time. Control cells received the Me 2 SO alone. To down-regulate protein kinase C, cells were treated with 1 M phorbol 12-myristate 13-acetate for 24 h in serum-containing media prior to transfer to serum-free media and treatment with A23187. For the transient experiment, 1.8 M A23187 was added to the cells for 2 min, after which the media containing the drug was removed, the cells were rinsed with phosphate-buffered saline, fresh serum-free media was added and the cells placed back in the incubator for the indicated amount of time. Controls were treated similarly with vehicle alone.
Collection and Immunoblotting-Cells were collected in lysis buffer (150 mM NaCl, 10 mM Tris-HCl, 1 mM EGTA, 1 mM EDTA, 0.2 mM sodium vanadate, 0.5% Nonidet P-40), containing 1 mM phenylmethylsulfonyl fluoride, 0.1 M okadaic acid, and a 10 g/ml concentration each of aprotonin, leupeptin, and pepstatin. Lysates were sonicated on ice, centrifuged, and protein concentrations in the supernatants were determined using a BCA assay (Pierce). The homogenates were diluted to a final concentration of 1 mg/ml in 2ϫ reducing stop buffer (0.25 M Tris-HCl, pH 6.8, 5 mM EDTA, 5 mM EGTA, 25 mM dithiothreitol, 2% SDS, and 10% glycerol, with bromphenol blue as the tracking dye). Equal amounts of protein from each sample were electrophoresed on 10% SDS-polyacrylamide gels, transferred to nitrocellulose, and probed with the indicated antibodies. After incubation with the appropriate horseradish peroxidase-conjugated secondary antibody, the blots were developed using ECL (Amersham). Densitometric analysis was used to quantitate the blots.
Calcium Imaging-Intracellular calcium levels were measured using the Fura-2 technique with ratiometric measurements as described previously (32) . In brief, cells were reseeded onto coverslips coated with 5 g/ml poly-D-lysine 2 days prior to experimentation. On the day of the experiment, cells were incubated with calcium-sensitive Fura-2 AM (10 M) (Teflabs) for 30 min at 37°C. The coverslips were then placed in a heated microchamber, and maintained at 35°C in RPMI 1640 media without phenol red (ICN), supplemented with antibiotics and 20 mM L-glutamine. Ratiometric measurements were performed with a Xenon light source and an intensifying CCD camera with IonWizard software (Ionoptix, Inc., Milton, MA). 4-Bromo-A23187, a non-fluorescent analog of the ionophore, was used for all studies.
32
P i Immunoprecipitation-Cells were placed in RPMI 1640 phosphate-free (P-free) media (ICN), supplemented with antibiotics and 20 mM L-glutamine, for 30 min, prior to the addition of 0.5 mCi/ml 32 P i (carrier-free, ICN) and prelabeled for 2 h before treatment with 0.15 M A23187. For the transient experiment, the cells were placed in P-free media for 30 min, 1.8 M A23187 was added for 2 min, after which the cells were rinsed with phosphate-buffered saline and changed to fresh P-free media, to which 32 P i was then added. After the indicated amount of time, the cells were collected in lysis buffer containing appropriate protease inhibitors. Cell lysates were boiled for 10 min, centrifuged, and the supernatant collected. A polyclonal tau antibody (34 g) was added to each sample, and incubated for 3 h at 4°C. Fifty microliters of washed protein A-Sepharose beads were added to each sample and incubated overnight at 4°C. The precipitates were washed 3 times with lysis buffer, and resuspended in 2ϫ reducing stop buffer. The samples were boiled for 15 min and the supernatants electrophoresed on 10% SDS-polyacrylamide gels. The proteins were transferred to nitrocellulose and probed with the monoclonal tau antibody, Tau-5. The blots were developed using diaminobenzidine, to assess total tau in each sample. The blots were then exposed to x-ray film, to assess the amount of radioactivity in each sample.
GSK-3␤ Immunoprecipitation-GSK-3␤ was immunoprecipitated from 300 g of protein using a monoclonal GSK-3␤ antibody (1.5 g), and the immune complex was captured with protein G-Sepharose beads. The precipitates were washed three times with lysis buffer, and the complex was removed from the beads by adding 35 l of 2ϫ reducing stop buffer and boiling for 15 min. The supernatant was electrophoresed on an 8% SDS-polyacrylamide gel, transferred to nitrocellulose, and blotted with the horseradish peroxidase-conjugated anti-phosphotyrosine antibody, RC20H (used at 1:2500 in 1% bovine serum albumin in borate saline). After being developed by ECL, the blot was stripped by incubating in a stripping buffer (62.5 mM Tris-HCl, 100 mM ␤-mercaptoethanol, 2% SDS, pH 6.7) at 50°C for 30 min. The blot was then washed, blocked in 5% milk/Tris-buffered saline with Tween 20 for 1 h, and re-probed with the monoclonal GSK-3␤ antibody to determine the protein levels that were immunoprecipitated.
RESULTS

A Low Concentration of A23187 Elicits a Prolonged Increase in Tau
Phosphorylation-To determine the effects of modest increases in intracellular calcium on tau phosphorylation, SH-SY5Y cells were treated with 0.15 M A23187 and collected at various times after the addition of ionophore. The samples were subsequently immunoblotted with Tau-5 antibody, which recognizes total tau, and Tau-1 antibody which recognizes tau only when it is dephosphorylated at residues 189 -207. The representative immunoblots in Fig. 1A demonstrate that Tau-1 immunoreactivity was decreased by 0.5 h after addition of 0.15 M A23187 and remained decreased for up to 4 h, indicating an increase in phosphorylation at this epitope. Therefore, tau phosphorylation is increased in response to 0.15 M A23187 by 0.5 h and remains elevated for up to 4 h. The A23187-induced increase in phosphorylation at the Tau-1 epitope remained elevated for up to 8 h, but by 24 h had returned to normal (data not shown). The data from three independent experiments were quantitated and the Tau-1 immunoreactivity in each sam-ple normalized to the amount of total tau as measured by Tau-5 immunoreactivity. The data were then presented as the relative increase in phosphorylation at the Tau-1 epitope in response to treatment with 0.15 M A23187 (Fig. 1B ). These data demonstrate that there is a significant, consistent ϳ60% increase in tau phosphorylation at the Tau-1 epitope after treating with the low concentration of A23187 for 1 and 2 h.
To analyze the selectivity of the calcium-induced increase in tau phosphorylation by a low concentration of A23187, samples were probed with a number of phosphorylation dependent tau antibodies. Treatment with the ionophore resulted in an increase in AT8 immunoreactivity. AT8 recognizes phosphoryl- To further elucidate the effect of A23187 on tau phosphorylation, the effects of increasing concentrations of A23187 on tau phosphorylation was examined. Cells were treated for 1 h with Me 2 SO alone, or increasing concentrations of A23187 up to 1.8 M and then immunoblotted with Tau-5 and Tau-1. These results indicate that tau phosphorylation is increased in response to low concentrations of ionophore, but decreased at high concentrations (Fig. 3) . The finding that tau is dephosphorylated in response to higher concentrations of ionophore is consistent with previous reports (19, 21) .
Because tau is phosphorylated in response to chronic treatment with a low concentration of A23187, but dephosphorylated when the cells were treated chronically with higher concentrations of A23187, cells were treated acutely with a high concentration of the ionophore. In this paradigm, cells were treated with 1.8 M A23187 or Me 2 SO for 2 min, and then returned to drug-free media. It was found that tau phosphorylation increased 0.5 h after a transient treatment with 1.8 M A23187 for 2 min at the Tau-1 and AT8 epitopes. No change was observed at the PHF-1 epitope (Fig. 4) . This increase in tau phosphorylation was also observed 4 h after the transient ionophore treatment (data not shown). These results indicate that a transient treatment with the high concentration of ionophore mimics the effect of chronic treatment with the low concentration of calcium ionophore. That is, tau phosphorylation is increased in a site selective manner in both paradigms. (Fig. 5A ), 1.8 M (Fig.  5B ), or transiently with 1.8 M 4-bromo-A23187 (Fig. 5C ). For each condition, a 100-s baseline was recorded, followed by the addition of the drug (denoted by the arrow). Although Fig. 5 only shows recordings out to 600 s, initial experiments were carried out to 20 min (data not shown). Because no differences were detected after 600 s with the low concentration or transient treatment with A23187, and the cells treated chronically with 1.8 M started to become non-adherent at longer time points, further imaging paradigms were not extended beyond this time point. Treatment with 0.15 M 4-bromo-A23187 resulted in a rapid, but modest, increase in intracellular calcium from a baseline of ϳ50 to ϳ75 nM. However, after approximately 300 s intracellular calcium levels returned to baseline, even though the drug remained on the cells (Fig. 5A). (Note: the different line characteristics seen in Fig. 5 is a result Tau change in recording speed from 1 record every 0.5 s for the first 400 s, to a speed of 1 record every 10 s thereafter.) Treatment with 1.8 M 4-bromo-A23187 also produced a rapid increase in intracellular calcium. However, calcium concentrations never returned to baseline, and after ϳ200 s continued to rise steadily during the remainder of the experiment (Fig. 5B) . In contrast, transient treatment with 1.8 M 4-bromo-A23187 for 2 min results in an intracellular calcium profile that was similar to chronic treatment with the low concentration in terms of temporal aspects. In Fig. 5C , the simple line arrow indicates where the drug was removed. The treatment results in a rapid increase in intracellular calcium. However, approximately 2 min after the drug is removed, the calcium levels return to baseline. This finding is particularly interesting because it demonstrates that transient increases in intracellular calcium, lasting 2-5 min, result in prolonged tau phosphorylation, that is not evident until 0.5 h after treatment, and remains elevated for at least 4 h. Fig. 6 . These data indicate that chronic treatment with the low concentration of ionophore (Fig. 6A ) or transient treatment with the high concentration (Fig. 6B) both result in an overall increase in tau [ 32 P]phosphorylation. Autoradiographs were quantitated and the 32 P incorporated into tau was normalized to the total amount of tau in the samples as determined from the Tau-5 blots. These results revealed a significant 43.7 Ϯ 3% (n ϭ 3) increase in tau phosphorylation in response to transient increases in calcium.
GSK-3␤ Is Likely Involved in the Calcium-induced Increase in Tau Phosphorylation in a Protein Synthesis Independent
Manner-Because a transient increase in intracellular calcium lasting only a few minutes elicited an increase in tau phosphorylation that was evident hours later, the possible involvement of protein synthesis was evaluated. Cells were pretreated for 15 min with 60 M cycloheximide, a protein synthesis inhibitor, then 0.15 M A23187 was added for an additional 2 h. Inhibition of protein synthesis did not prevent the increase in tau phosphorylation elicited by treatment with the ionophore (Fig. 7) .
Because the increase in tau phosphorylation occurred in response to a transient increase in intracellular calcium, the possible involvement of Ca 2ϩ /calmodulin-dependent protein kinase II and/or protein kinase C was evaluated. Treatment of cells with 30 M KN-62 or KN-93, selective Ca 2ϩ /calmodulindependent protein kinase II inhibitors (33, 34) or chronic treatment with 1 M phorbol 12-myristate 13-acetate, which selectively depletes protein kinase C, did not inhibit the A23187-induced increase in tau phosphorylation (data not shown). These data indicate that Ca 2ϩ /calmodulin-dependent protein kinase II or protein kinase C are not involved in the calciuminduced increase in tau phosphorylation. The Tau-1 and AT8 epitopes are phosphorylated by GSK-3␤ in vitro and in situ (35, 36) . Therefore, the effect of inhibition of GSK-3␤ on the calcium-induced increase in tau phosphorylation was examined. Lithium has been shown to be an uncompetitive, selective inhibitor of GSK-3␤ (37, 38) . Pretreatment of cells overnight with 10 mM lithium chloride resulted in the elimination of the increase in tau phosphorylation in response to the low dose of A23187 (Fig. 8) . These data strongly support a role for GSK-3␤ in the calcium-mediated increase in tau phosphorylation.
To further analyze the role of GSK-3␤ in the calcium-mediated increase in tau phosphorylation, the effects of the tyrosine kinase inhibitor, genistein were examined because GSK-3␤ is activated by tyrosine phosphorylation (23) . Cells were pretreated with 100 M genistein for 10 min, then treated with 0.15 M A23187 for 1 h. Treatment with the tyrosine kinase inhibitor completely blocked the increase in tau phosphorylation in response to A23187 (data not shown). These data indicate that the calcium-mediated increase in tau phosphorylation is dependent on tyrosine phosphorylation and further point to GSK-3␤ as a possible candidate.
GSK-3␤ Is Tyrosine Phosphorylated in Response to
Treatment with 0.15 M A23187-Previous studies have shown that there are tyrosine kinases that are selectively activated by increases in intracellular calcium (39) . Therefore, cells were incubated in the absence or presence of 0.15 M A23187 for 1 h and GSK-3␤ was immunoprecipitated. The samples were then probed with the anti-phosphotyrosine antibody, RC20H, which recognizes proteins that are phosphorylated on tyrosine residues. The blots were then stripped and re-probed with the GSK-3␤ antibody to examine the total amount of GSK-3␤ that was immunoprecipitated. Representative immunoblots are shown in Fig. 9 and demonstrate that a modest transient increase in calcium results in a prolonged increase in GSK-3␤ tyrosine phosphorylation. Quantitation of the levels of tyrosine phosphorylation relative to the levels of GSK-3␤ in the precipitates revealed that transient calcium increases resulted in a sustained, significant 35 Ϯ 8% (n ϭ 3) increase in the tyrosine phosphorylation of GSK-3␤. 
DISCUSSION
The primary goal of this study was to examine the relationship between temporal changes in intracellular calcium con- centrations and alterations in the phosphorylation state of tau. Our data indicate that transient increases in intracellular calcium concentrations result in prolonged, site-specific increases in tau phosphorylation. A previous report demonstrated that the cytoskeletal protein, MAP-2 is phosphorylated in response to sustained increases in intracellular calcium in neonatal rat brain slices (3) . However, to our knowledge, this present study is the first demonstration of prolonged phosphorylation of a cytoskeletal protein in response to a calcium transient, and further that increases in GSK-3␤ tyrosine phosphorylation are likely to be responsible for the increased tau phosphorylation. Temporal changes in intracellular calcium clearly play important roles in mediating phosphorylation-dependent cell function (for reviews, see Refs. 1 and 2), although the majority of studies have focused on transcription factors and specific enzymes. For example, in cultured dorsal root ganglion neurons, calcium transients of differing durations play important roles in regulating the activation of specific transcription factors. In dorsal root ganglion neurons, levels of phosphorylated cAMPresponse element-binding protein remained elevated for at least 25 min after a calcium transient of 5 min (40). Dolmetsch et al. (41) demonstrated that different transcriptional factors are activated in B lymphocytes depending on the amplitude and duration of the calcium signal. Specifically, NF-B and c-Jun N-terminal kinase were activated by large calcium transients, while nuclear factor of activated T-cells was activated by a low, sustained increase in intracellular calcium. Furthermore, the activation of NF-B and C-Jun N-terminal kinase was sustained for 16 min after the calcium spike had terminated, indicating that the pathways retained a memory of the calcium transient that outlasted the calcium signal itself (41) . It has also been shown that transient increases in calcium due to N-methyl-D-aspartate receptor activation result in long lasting increases in the phosphorylation state of protein kinase C (42) . We have demonstrated a similar occurrence in our model with the cytoskeletal protein tau, in that a short calcium signal results in a persistent increase in phosphorylation. Because phosphorylation regulates tau function (10 -13), increases in intracellular calcium of short duration are likely to result in persistent changes in the cytoskeleton. Indeed, there is evidence to suggest that tau plays a role in axonal outgrowth (43, 44) , and that tau is differentially phosphorylated during this process (45) . Our results indicate that calcium transients result in long lasting changes in the phosphorylation state of tau. These changes in the phosphorylation state of tau may play a critical role in the cytoskeletal rearrangement which takes place during development and synaptic plasticity.
Previous studies have demonstrated that insulin and other growth factors can modulate the activity of GSK-3␤ within the cell (35, 36, 46 -48) . Although the majority of studies have focused on inhibition of GSK-3␤ activity due to increased phosphorylation of Ser 9 in response to different factors (35, 46, 48) , increased activity in response to tyrosine phosphorylation have been observed. GSK-3␤ is tyrosine phosphorylated on Tyr 216 and this results in a significant increase in GSK-3␤ activity (23) . Furthermore, stimulation of human neuroblastoma cells with insulin results in a transient increase in GSK-3␤ tyrosine phosphorylation with a concomitant increase in GSK-3␤ activity (36) . Because tau is an in situ substrate of GSK-3␤ (49, 50) , modulation of cellular GSK-3␤ activity results in changes in tau phosphorylation (35, 36, 50) . However, the findings in this paper are novel for two reasons. We demonstrate for the first time that the tyrosine phosphorylation state of GSK-3␤ is persistently elevated by a calcium transient and that GSK-3␤ can be activated through a calcium-dependent mechanism which results in increased tau phosphorylation. The fact that GSK-3␤ only contains one site that is tyrosine phosphorylated (Tyr 216 ) (23) and that an increase in tyrosine phosphorylation of GSK-3␤ was detectable and significant using a phosphotyrosine antibody an hour after the calcium transient further illustrates the significance of this increase. These findings are particularly exciting as a family of tyrosine kinases with homology to pp125
FAK which are activated in response to increases in intracellular calcium have recently been described (39, 51, 52) . These kinases, termed proline-rich tyrosine kinase 2 (PYK2), are highly enriched in brain (39, 51, 52) and once activated by increases in intracellular calcium (39, 53) tyrosine phosphorylate specific substrates (39) . Considering this data and our findings, it is likely that PYK2 or a related tyrosine kinase is activated by the calcium transients which in turn results in tyrosine phosphorylation and persistent activation of GSK-3␤ and thus a sustained increase in tau phosphorylation. However, further studies are required to examine this hypothesis.
In this study, transient increases in intracellular calcium resulted in increased phosphorylation of tau only within the Tau-1 epitope. However, the number of specific epitopes examined with the different phosphorylation dependent antibodies was limited, and given that tau has the potential to be phosphorylated on at least 25 sites (54, 55) , it is likely that the phosphorylation of other sites are modulated by the calcium transients as well. Previous studies have shown that GSK-3␤ does not phosphorylate sites that are contained within AT180 and AT270 epitopes (36, 56) . Therefore it is not surprising that the immunoreactivity of those antibodies was not altered by the calcium transients as the resulting changes in tau phosphorylation are apparently dependent upon GSK-3␤. Furthermore, given the substrate specificity and the consensus sequences of GSK-3␤ (57), and previous findings (35, 50) , the lack of A23187-mediated changes at Ser 262/356 as indicated by reactivity with 12E8 (27) was expected. Overexpression of GSK-3␤ has been shown to increase Ser 396/404 phosphorylation as indicated by an increase in PHF-1 reactivity (35, 50) . However, GSK-3␤ overexpression resulted in a much more robust change in Tau-1 immunoreactivity compared with PHF-1, indicating that sites within the Tau-1 epitope may be preferentially phosphorylated by GSK-3␤ (35) . Considering the mechanism used to activate GSK-3␤ in the present study, a modest transient increase in calcium and increased tyrosine phosphorylation, it is likely the lack of changes in PHF-1 could be due to a "controlled" activation which may then result in phosphorylation of preferred sites within the Tau-1 epitope by GSK-3␤.
In conclusion, this study demonstrates for the first time that tau phosphorylation is persistently increased in response to calcium transients of 2-5 min. Furthermore, the calcium-induced increase in tau phosphorylation is dependent upon FIG. 9 . Transient increases in intracellular calcium result in an increase in tyrosine phosphorylation of GSK-3␤. Cells were treated with Me 2 SO (Ϫ) or 0.15 M A23187 (ϩ) for 1 h. GSK-3␤ was immunoprecipitated from the samples. The precipitates were electrophoresed and immunoblotted with the RC20H antibody which detects phosphotyrosines. The blots were then stripped and re-probed with a GSK-3␤ antibody to determine the amount of GSK-3␤ that was immunoprecipitated from each sample. These representative immunoblots show that tyrosine phosphorylation of GSK-3␤ increases in response to calcium transients.
GSK-3␤ activity and correlates with an increase in tyrosine phosphorylation of GSK-3␤. Both GSK-3␤ and tau are enriched in growth cones and the distal regions of growing axons (43, 58) , and there is a spatial gradient of Tau-1 within growing axons (45) . Therefore, it can be postulated that calcium transients play important roles in regulating GSK-3␤-mediated tau phosphorylation and contribute to the cytoskeletal remodeling events that occur during neuronal development and remodeling.
